Revatio Powder, For Suspension
Product Images NDC 58151-385

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Revatio (NDC 58151-385). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Instructions For Use Figure A (Image 01)

This is a description of a bottle adaptor used for a REVATIO oral suspension. It includes a barrel, plunger, and indicates a "Discard after" date for the suspension. The image referred to as Figure A likely demonstrates the assembly or usage of the adaptor.*

FDA Label Image

Instructions For Use Figure B (Image 02)

FDA Label Image

Instructions For Use Figure C (Image 03)

FDA Label Image

Instructions For Use Figure D (Image 04)

FDA Label Image

Instructions For Use Figure E (Image 05)

FDA Label Image

Instructions For Use Figure F (Image 06)

FDA Label Image

Instructions For Use Figure G (Image 07)

FDA Label Image

Instructions For Use Figure H (Image 08)

FDA Label Image

Instructions For Use Figure I (Image 09)

FDA Label Image

Sildenafil Citrate Structural Formula (Image 10)

FDA Label Image

Figure 1. Effects Of Other Drugs On Sildenafil Pharmacokinetics (Image 11)

Interacting drug fold change and 90% CI recommendations are provided for various medications including Atorvastatin, Oral Contraceptives, Ritonavir, and Saquinavir. The text also mentions that no dose adjustments are required for Atorvastatin AUC. Additionally, it references the accumulation ratio of AUC from Day 1 to Day 7 relative to Sildenafil alone, and mentions that there is no benefit on exercise capacity when sildenafil is added to bosentan therapy.*

FDA Label Image

Figure 2. Effects Of Sildenafil On Other Drugs (Image 12)

FDA Label Image

Figure 3. Change From Baseline In 6-minute Walk Distance (meters) At Weeks 4, 8, And 12 In Super-1: Mean (95% Confidence Interval) (Image 13)

FDA Label Image

Figure 4. Placebo-corrected Change From Baseline In 6-minute Walk Distance (meters) At Week 12 By Study Subpopulation In Super-1: Mean (95% Confidence Interval) (Image 14)

FDA Label Image

Figure 5. Kaplan-meier Plot Of Time (in Days) To Clinical Worsening Of Pah In Paces-1 (Image 15)

FDA Label Image

Figure 6. Percentage Change From Baseline In Vo2peak: Mean (95% Confidence Intervals) (Image 16)

FDA Label Image

Bottle Label Revatio 20 mg (Image 17)

FDA Label Image

Carton Label Revatio 10 mg/12.5 mL (Image 18)

This is a description of the drug Revatio (sildenafil) Injection, with a strength of 10 mg/12.5 mL. It is a sterile single-dose solution for intravenous use. The medication is stored at a controlled room temperature between 20°C to 25°C (68°F to 77°F). Each milliliter of the solution contains 1.124 mg of sildenafil citrate, 505 mg of dextrose, and water for injection. The drug is distributed by Vit Specialty LLC in Morgantown, WV, USA. The dosage information and prescribing details can be found in the accompanying literature.*

FDA Label Image

Carton Label Revatio 10 mg/ml (Image 19)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.